Xylitol Nasal Spray Prevents SARS-CoV-2 Infection

The sophisticated American consumer has grown accustomed to the gold standard for drug and health products—the prospective randomized, double-blind, placebo-controlled trial (RCT). Operation Warp Speed was supposed to be a large-scale RCT-driven churning machine to aid the nation in determining what treatment is best for COVID-19 prevention and treatment.

OWS failed to deliver three years worth of products (remdesivir and baricitinib and molnupiravir) and inconclusive small trials of products doctors have found effective, including generic antivirals or anticoagulants. OWS did NOT test cost-effective, simple and affordable prevention strategies. These RCTs, which were conducted outside the United States, have provided us with important results.

Balmforth and colleagues conducted a prospective placebo-controlled double-blind trial of a new xylitol-based drug. nasal spray Two hospitals in Uttar Pradesh, India were used to prevent SARS-CoV-2 infections in healthcare workers. Xylitol, which is well-known for its anti-infective as well anti-inflammatory properties, is used in XLEAR nasal Spray and antiinfective chewing gum to prevent tooth decay.

Balmforth discovered that SARS-CoV-2 confirmed by serology was 71% lower when xylitol was used than placebo. [36 cases (13.1 percent) vs. 97 cases (34.5 percent); odds ratio [OR] 0.29 (95 percent CI; 0.18–0.45), p < 0.0001]. The test group also had fewer clinical symptoms. [57 cases (17.6 percent) vs. 112 cases (34.6 percent); OR 0.40, (95 percent CI; 0.27–0.59), p < 0.0001].

Xylitol did not cause any adverse reactions. A smaller study on xylitol nasal treatment in mild COVID-19 cases showed that persistent loss may be prevented by using xylitol during acute congestion.

The RCTs of topical nasal sprays or gargles for COVID-19 have impressed me far more than the RCTs with intravenous or oral drugs. Xylitol, available in U.S. pharmacies as XLEAR, is one option for local nasopharyngeal treatment and protection of COVID-19.

Reposted from Peter A. McCullough’s Substack

◇ References:

Balmforth D, Swales JA, Silpa L, Dunton A, Davies KE, Davies SG, Kamath A, Gupta J, Gupta S, Masood MA, McKnight Á, Rees D, Russell AJ, Jaggi M, Uppal R. Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial. J Clin Virol. 2022 Oct;155:105248. doi: 10.1016/j.jcv.2022.105248. Epub 2022 Jul 25. PMID: 35952426; PMCID: PMC9313533.

Soler E, de Mendoza A, Cuello VI, Silva-Vetri MG, Núñez ZH, Ortega RG, Rizvi SA, Sanchez-Gonzalez M, Ferrer G. Intranasal Xylitol for the Treatment of COVID-19 in the Outpatient Setting: A Pilot Study. Cureus. 2022 Jul 23rd;14(7):e27182. doi: 10.7759/cureus.27182. PMID: 36039203; PMCID: PMC9395150.

XLEAR Nasal Spray & Irrigation Website

These EpochHealth articles are intended to be used as information and not as a substitute or replacement for individual medical advice. For personal medical advice, diagnosis, and treatment, please consult a trusted professional. Have a question? Send us an email at [email protected]

*As an Amazon Associate I earn from qualifying purchases